179 related articles for article (PubMed ID: 31064155)
21. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
22. Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.
Kawada JI; Ando S; Torii Y; Watanabe T; Sato Y; Ito Y; Kimura H
Cancer Med; 2018 Apr; 7(4):1275-1284. PubMed ID: 29522278
[TBL] [Abstract][Full Text] [Related]
23. Composite Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia and Follicular Lymphoma: A Clinicopathological Study of Six Cases.
Jelloul FZ; Chen QH; Yang T; Haghi N; Brody J; Zhang X; Sheikh-Fayyaz S
Int J Surg Pathol; 2018 Apr; 26(2):135-144. PubMed ID: 29069998
[TBL] [Abstract][Full Text] [Related]
24. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Shouse G; Chen L; Siddiqi T; Muir A; Brown JR; Spurgeon SE; Danilov AV
Leuk Lymphoma; 2024 Jun; ():1-4. PubMed ID: 38836342
[No Abstract] [Full Text] [Related]
26. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
27. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
28. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, spectroscopic and computational studies on hydrogen bonded charge transfer complex of duvelisib with chloranilic acid: Application to development of novel 96-microwell spectrophotometric assay.
Darwish IA; Almehizia AA; Sayed AY; Khalil NY; Alzoman NZ; Darwish HW
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120287. PubMed ID: 34455386
[TBL] [Abstract][Full Text] [Related]
30. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.
Pongas G; Cheson B
Blood Lymphat Cancer; 2021; 11():55-66. PubMed ID: 34354386
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah FA; Blaize JP; Bryan LJ
Onco Targets Ther; 2018; 11():4817-4827. PubMed ID: 30147333
[TBL] [Abstract][Full Text] [Related]
33. Copanlisib in the Treatment of Relapsed Follicular Lymphoma: Utility and Experience from the Clinic.
Chauhan AF; Cheson BD
Cancer Manag Res; 2021; 13():677-692. PubMed ID: 33531838
[TBL] [Abstract][Full Text] [Related]
34. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
35. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
36. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
37. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
38. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda WG; Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Caimi P; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Harris NL; Hernandez-Ilizaliturri F; Hoppe RT; Horwitz SM; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Martin MG; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Snyder ED; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2017 Mar; 15(3):293-311. PubMed ID: 28275031
[TBL] [Abstract][Full Text] [Related]
39. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
40. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
